Loading
For treatments that will not cure, what matters is how long the treatment keeps working without becoming unbearable, and how the person feels. Trials should measure both of those as their main results.
In palliative-intent settings, trials adopt time to treatment failure (progression, death or discontinuation for toxicity or patient choice) together with a validated QoL instrument (EORTC QLQ-C30 or disease module) analysed as time to definitive deterioration, as co-primary endpoints, with OS as the principal secondary endpoint. PFS alone rewards drugs that delay scan progression while making patients feel worse.
Shares Patients lack understanding, navigation and agency, Progression-free survival (PFS), Overall survival (OS), Toxicity and quality of life are undervalued.
Shares Progression-free survival (PFS), Overall survival (OS), Trial design, endpoints and cost, Toxicity and quality of life are undervalued.
Shares Progression-free survival (PFS), Overall survival (OS), Trial design, endpoints and cost.
Shares Patients lack understanding, navigation and agency, Trial design, endpoints and cost.
Shares Patients lack understanding, navigation and agency, Trial design, endpoints and cost.
Shares Progression-free survival (PFS), Trial design, endpoints and cost, Toxicity and quality of life are undervalued.
Shares Patients lack understanding, navigation and agency, Trial design, endpoints and cost, Toxicity and quality of life are undervalued.
Shares Progression-free survival (PFS), Overall survival (OS), Trial design, endpoints and cost, Toxicity and quality of life are undervalued.